NOXXON Pharma N.V.: Noxxon Reports 2021 Financial Results

Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME)

Related Keywords

Germany ,Illinois ,United States ,Paris ,France General ,France ,Chicago ,American ,Eileenm Oreilly ,Guillaume Van Renterghem ,Thomastw Seufferlein ,Arthur Rouill ,Bryan Jennings ,Aram Mangasarian ,Frank Giordano ,Susan Coles ,Pharmanv Euronext ,Merck Keytruda ,Jose Saro ,Elena Gabriela Chiorean ,Joyce Fearon ,American Society Of Clinical Oncology ,Linkedin ,Twitter ,Merck Co ,Company Stock Option Plan ,Merck Sharp Dohme Corp ,Society For Neuro ,Life Sciences ,Regulatory News ,Euronext Growth Paris ,Annual Report ,Advisory Board ,Supervisory Board ,Senior Vice President Corporate Strategy ,General Counsel ,Vivet Therapeutics ,Annual Meeting ,Clinical Oncology ,Cancer Phase ,Atlas Special Opportunities ,Stock Option ,Brain Cancer ,Pancreatic Cancer ,Solid Tumors ,Merck Sharp Dohme ,Executive Officer ,Media Relations ,Noxxon ,Dharma ,Reports ,021 ,Financial ,Results ,